The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $57.18

Today's change+0.09 +0.16%
Updated December 26 4:01 PM EST. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $57.18

Today's change+0.09 +0.16%
Updated December 26 4:01 PM EST. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd up (U.S.)$0.09

Teva Pharmaceutical Industries Ltd closed up Friday by (U.S.)$0.09 or 0.16% to (U.S.)$57.18. Shares have lost 1.41% over the last five days, but sit 3.00% below their 52-week high. This security has outperformed the S&P 500 by 30.60% during the last year.

Key company metrics

  • Open(U.S.) $57.05
  • Previous close(U.S.) $57.09
  • High(U.S.) $57.67
  • Low(U.S.) $56.96
  • Bid / Ask-- / --
  • YTD % change+42.66%
  • Volume913,846
  • Average volume (10-day)3,992,675
  • Average volume (1-month)3,490,533
  • Average volume (3-month)4,136,414
  • 52-week range(U.S.) $39.53 to (U.S.) $58.95
  • Beta0.64
  • Trailing P/E17.79×
  • P/E 1 year forward11.29×
  • Forward PEG8.30×
  • Indicated annual dividend(U.S.) $1.35
  • Dividend yield2.37%
  • Trailing EPS(U.S.) $3.21
Updated December 26 4:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+13.38%

Based on its net profit margin of 13.38%, Teva Pharmaceutical Industries Ltd is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.10%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,0585,0455,0015,430
Total other revenue--------
Total revenue5,0585,0455,0015,430
Gross profit2,8092,6612,6972,894
Total cost of revenue2,2492,3842,3042,536
Total operating expense3,9464,1204,0294,870
Selling / general / administrative1,2401,2111,2691,448
Research & development412344353411
Depreciation / amortization3717--
Interest expense (income), net operating--------
Unusual expense (income)4216986475
Other operating expenses, total--------
Operating income1,112925972560
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1,028847891501
Income after tax868745748387
Income tax, total160102143114
Net income876748744380
Total adjustments to net income0------
Net income before extra. items876748744380
Minority interest13343
Equity in affiliates-5---8-10
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items876748744380
Inc. avail. to common incl. extra. items876748744380
Diluted net income878748744380
Dilution adjustment200--
Diluted weighted average shares861857852847
Diluted EPS excluding extraordinary itemsvalue per share1.020.870.870.45
Dividends per sharevalue per share0.340.350.340.32
Diluted normalized EPSvalue per share1.061.050.960.88